13 May 2021 - People living with migraine will no longer face the financial headache of forking out thousands of dollars a year on medication, after a new drug was introduced to the Pharmaceutical Benefits Scheme.
From June 2021, Emgality (galcanezumab) will be available on the PBS for 10,000 people who live with migraines.
Raphaella Crosby, founder of Migraine Australia, said this was a “massive win” for people who suffer from migraines.
“The 10,000 number listed on budget papers we think might be a typo, or it’s health department officials severely underestimating the migraine community again.
“It’s more likely to be 100,000.”